|
|
  |
 |
  |
Clinical
Measures for Health Center Grantee Performance
Reviews –
Calendar Year 2006
| Performance
Measure: |
# 6 |
|
Activity
Code(s): |
H 80 |
|
| Percentage
of adults with abnormal lipid profile, whose
levels are under control. |
| |
| Operational
Definition: |
Numerator:
|
# of males 35-79 and females
45-79 in the denominator with documented
lipids levels in goal range per guideline.
LDL is the most commonly used dyslipidemia/or
abnormal lipid profile measure, however,
other lipids such as total cholesterol,
and/or HDL, and/or triglycerides may be
used per guideline.
The goal for LDL levels, per current
guidelines:
a. LDL < 100 if CHD1 or high 10 year
CHD risk3
b. LDL < 130 if no CHD but > 2 risk
factors2 or moderate 10 year CHD risk3
c. LDL < 160 if no CHD and 0-1 risk
factors2 or low 10 year CHD risk3
1. CHD includes any clinical coronary
heart disease, symptomatic carotid artery
disease, peripheral arterial disease,
abdominal aortic aneurysm.
2. The following are risk factors to be
counted:
- Cigarette smoking
- Hypertension (BP 140/90 mmHg or on
antihypertensive medication)
- Low HDL cholesterol (<40 mg/dl)*
- Family history of premature CHD (CHD
in male first degree
relative <55 years; CHD in female
first degree relative <65 years)
- Age (men 45 years; women 55 years)
- HDL cholesterol 60 mg/dL counts as
a "negative" risk factor;
its presence removes one risk factor
from the total count.
3. CHD 10 year risk calculator: http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof |
| Denominator: |
# of all males age 35-79 plus females
age 45-79 with at least one encounter
for any reason or service during the prior
calendar year, and who have had either
a prior diagnosis of abnormal serum lipids
or a prior laboratory test result with
abnormal serum lipid (high total cholesterol,
high LDL, high triglyceride, low LDL).
|
| Unit & Text:
|
numerator count / denominator count x
100 = % |
| |
|
National Numeric
Benchmark: |
HP2010 12-14 goal (all adults): <17%
with elevated total cholesterol (>83%
in control).
HEDIS goal (i.e. those with prior cardiovascular
event): 68% of commercial and 41% of Medicaid
plans controlled with LDL<130.
Health Disparities Collaborative goal:
> 60%.
|
Data
Sources
and Data Issues:
|
From registry or EHR/EMR if available.
If chart audit, then sample from the
sample frame of persons meeting denominator
criteria.
Some health centers should be collecting
this data, since control of persons with
a prior cardiovascular event is part of
the HEDIS data set reporting. It may require
sampling and manual record abstraction
by the Grantee’s QA committee. |
| |
| Background/significance
of the measure: |
|
Cardiovascular disease (CVD) is the leading
cause of death in the United States. Some
15 million Americans suffer from coronary
artery disease (CAD), the most common
form of heart disease, in which the coronary
arteries narrow due to plaque formation.
CAD is the leading cause of premature,
permanent disability in the U.S. labor
force, accounting for 19 percent of disability
allowance by the Social Security Administration.
One critical (and modifiable) risk factor
for CAD is elevated cholesterol. Over
106 million American adults (49 and 46
percent of men, and women, respectively)
have total blood cholesterol levels that
are higher than desirable. Effective cholesterol
management can help reduce the huge economic
burden of cardiovascular disease in the
United States, estimated to be more than
$393.5 billion in 2005, with heart disease
accounting for $254.8 billion. Management
of serum cholesterol, especially low-density
lipoprotein (LDL-C), is an important and
effective way to prevent and reduce the
suffering and disability caused by CAD.
Less than half of those who qualify for
cholesterol-lowering therapy are receiving
it.
Elevated levels of cholesterol, as well
as others such as triglycerides, (i.e.
“dyslipidemia”) is well recognized
as a leading concern by the general public
and health professionals, insurers (HEDIS)
and government (GPRA and HP2010) and HDC:
http://www.healthdisparities.net/hdc/html/collaboratives.topics.cvd.aspx
(measure 5)
This measure is a good proxy for all
adult care, not limited to only persons
with specific conditions, but rather directed
towards the need for universal screening,
follow-up and intervention when indicated.
It links provider education, patient education,
screening and follow-up.
see Adult Treatment Panel III (ATPIII):
http://www.nhlbi.nih.gov/guidelines/cholesterol/
http://www.nhlbi.nih.gov/about/ncep/index.htm
|
 |